Currently, seven ICIs are approved for the treatment of a number of advanced cancers.3 The anti‐PD1 Pembrolizumab and Nivolumab, and the anti‐CTLA4 ipilimumab were the first to be approved for the treatment of metastatic melanoma. The gene discussed is CTLA4; the disease is cancer.